A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.

Roni T FalkAnnetine Cathrine StaffGary BradwinS Ananth KarumanchiRebecca Troisi

Published in: Cancer causes & control : CCC (2016)

There was no evidence of an increased breast cancer risk associated with circulating levels of pro-angiogenic markers VEGF and PlGF or a reduced risk with circulating levels of anti-angiogenic marker sFlt-1.

Keyphrases

breast cancer risk
prostate cancer
clinical trial
study protocol
endothelial cells
phase iii
phase ii
randomized controlled trial
benign prostatic hyperplasia
postmenopausal women